Results 61 to 70 of about 1,785 (194)
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia
International Journal of Infectious Diseases, 2021 Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (IACR)
Antoni Torres +9 more
doaj +1 more source
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
, 2019 Omadacycline is a semisynthetic tetracycline antibiotic. Phase III clinical trial results have shown that omadacycline has an acceptable safety profile in the treatment of acute bacterial skin and skin structure infections and community-acquired ...
File, Thomas M. +5 more
core +1 more source
Fecal Pharmacokinetics and Gut Microbiome Effects of oral Omadacycline Versus Vancomycin in Healthy Volunteers [PDF]
BACKGROUND: Clostridioides difficile infection (CDI) is a common healthcare-associated infection with limited treatment options. Omadacycline, an aminomethylcycline tetracycline, has potent in vitro activity against C difficile and a low propensity to ...
Jo, Jinhee +11 more
core +1 more source
Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma +6 more
wiley +1 more source
MicrobiologyOpen, Volume 15, Issue 3, June 2026.A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Blanca Lorente‐Torres +13 more
wiley +1 more source
, 2022 In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus
Yi Zhang (9093) +8 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 2, February 2026.ABSTRACT To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune‐related adverse events (irAEs) after treatment with sintilimab (PD‐1 inhibitor) in combination with thymosin alpha‐1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
Ting Li +3 more
wiley +1 more source
Omadacycline for Community-Acquired Bacterial Pneumonia
New England Journal of Medicine, 2019 Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is active against common pathogens that cause community-acquired bacterial pneumonia.In a double-blind trial, we randomly assigned (in a 1:1 ratio) adults with community-acquired ...
Roman, Stets +14 more
openaire +2 more sources
Case Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.Entamoeba histolytica is an amebic protozoan that is often asymptomatic, with many patients being asymptomatic carriers. However, 10 percent of cases manifest with amebic dysentery and, less commonly, amebic liver abscesses. Amebic liver abscesses are the most common extraintestinal manifestation of E. histolytica.
Jamal A. Anthony +3 more
wiley +1 more source
Omadacycline Enters the Ring: A New Antimicrobial Contender [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018 Omadacycline is a novel aminomethylcycline approved for the treatment of community‐acquired bacterial pneumonia and acute bacterial skin and skin structure infections. This article reviews existing data pertaining to the biochemistry, mechanism of action, pharmacokinetics/pharmacodynamics, in vitro activity, and current progress with omadacycline in ...
Katie E. Barber +4 more
openaire +2 more sources